Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 8/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | CLK1 | P49759 | 6/20 | 1.00 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 1.00 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.67 |
| ▸ | CDK2 | P24941 | 2/20 | 0.67 |
| ▸ | CDK9 | P50750 | 2/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.66 |
| ▸ | CDK1 | P06493 | 4/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.66 |
| ▸ | PRKACA | P17612 | 4/20 | 0.66 |
| ▸ | PRKACG | P22612 | 4/20 | 0.66 |
| ▸ | PRKACB | P22694 | 4/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488162 | 1.00 | GSK3B (1.00) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL20030496 | 0.84 | DYRK1A (0.72) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL145566 | 0.82 | GSK3B (0.70) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL3658484 | 0.82 | DYRK1A (1.00) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL12701223 | 0.82 | GSK3B (0.79) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL3818537 | 0.81 | DYRK1A (0.68) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL29534011 | 0.81 | DYRK1A (0.68) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL4564892 | 0.81 | DYRK1A (0.68) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| SCHEMBL3615777 | 0.80 | GSK3B (0.67) | GSK3BCDK5CDK5R1DYRK1ACLK1 | |
| Meriolin 1 SCHEMBL2241315 | 0.80 | CDK9 (1.00) | GSK3BCDK5CDK5R1DYRK1ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789650-A | 2-amino-4-indolyl pyrimidine compound and preparation system and application thereof | 安徽理工大学 | 2023-09-22 | — | — | CN | claimed |
| CN-112174938-A | 4-indole-2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2021-01-05 | — | — | CN | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| WO-2023178928-A1 | 2-AMINO-4-INDOLYL PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 中国药科大学 | 2023-09-28 | — | — | WO | disclosed |
| CN-116789650-A | 2-amino-4-indolyl pyrimidine compound and preparation system and application thereof | 安徽理工大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-115925686-A | Meridianin derivatives, coupling synthesis method and application thereof promoted by Lewis acid | 贵州医科大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| CN-113563310-B | 4- (1-methylindol-3-yl) pyrimidine derivative and application thereof | 浙江工业大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-113563310-B | 4- (1-methylindol-3-yl) pyrimidine derivative and application thereof | 浙江工业大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-113563310-A | 4- (1-methylindol-3-yl) pyrimidine derivative and application thereof | 浙江工业大学 | 2021-10-29 | — | — | CN | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | disclosed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
| EP-0422178-A1 | PYRIMIDINE DERIVATIVES. | ICI PLC (GB) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | GSK3B 110/4885CDK5 14/4885CDK5R1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.